Treatment of lentigo maligna with tazarotene 0.1% gel.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 14699375.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
Medical subject headings
- Dermatologic Agents
- Hutchinson's Melanotic Freckle
- Nicotinic Acids